NEW YORK (TheStreet) -- What's the deal with Alexion Pharmaceutical (ALXN) -- literally? TheStreet's Jim Cramer and "Mad Money" Research Director Nicole Urken discussed what traders can expect from the drastic acquisition talk surrounding the pharma company.

While the M&A prospects for the broader markets have seemed rather dull this year, biotech has been red hot, with huge acquisitions lighting up the financial headlines throughout 2013.

Both Bloomberg and Reuters have reported that a deal between Alexion and Roche is being talked about and Cramer said that they are not backing down from those claims.

Furthermore, Oppenheimer & Company also expects a deal and have priced it between $148 and $208. The estimates represent a premium of at least 27%, based on the lower end of the estimates' range and from Monday's closing price of $107.93.

Cramer did say that he already thinks Alexion is overvalued, but that he thought that about other pharmaceutical companies that have been takeover targets this year.

While some may argue over valuation, he did conclude, "I gotta believe there's a deal and it's going to be well in excess of where the stock is now."

-- Written by Bret Kenwell in Petoskey, Mich.

Bret Kenwell currently writes, blogs and also contributes to Robert Weinstein's Weekly Options Newsletter. Focuses on short-to-intermediate-term trading opportunities that can be exposed via options. He prefers to use debit trades on momentum setups and credit trades on support/resistance setups. He also focuses on building long-term wealth by searching for consistent, quality dividend paying companies and long-term growth companies. He considers himself the surfer, not the wave, in relation to the market and himself. He has no allegiance to either the bull side or the bear side.

More from Opinion

Red Hat CFO Tells TheStreet: Tech Trends Are Still in Our Favor

Red Hat CFO Tells TheStreet: Tech Trends Are Still in Our Favor

Throwback Thursday: Intel Edition

Throwback Thursday: Intel Edition

Intel's Next CEO Should Try Harder to Protect Its Flanks Against AMD and Others

Intel's Next CEO Should Try Harder to Protect Its Flanks Against AMD and Others

3 Warren Buffett Stock Picks That Could Be Perfect for Your Retirement Portfolio

3 Warren Buffett Stock Picks That Could Be Perfect for Your Retirement Portfolio

Wednesday Wrap-Up: GE and Facebook

Wednesday Wrap-Up: GE and Facebook